Shire's mission is to enable people with life-altering conditions to lead better lives. The pharmaceutical company focuses on developing treatments in neuroscience, rare diseases and internal medicine.
Boston Children's and Shire entered a broad three-year research collaboration in rare diseases in November of 2012. Our partnership seeks to advance new treatments for a number of rare pediatric diseases by combining the research and clinical expertise of Boston Children's with Shire's therapeutic development and commercialization capabilities. Each year, Shire and Boston Children's jointly issue requests for proposals (RFPs) to Boston Children's researchers.
Under the agreement, Shire funds and collaborates on selected Boston Children's research programs. The emphasis is on drugs that could become a candidate for development in under three years. Following the completion of these research programs, Shire will have an exclusive option to enter into a licensing agreement for each candidate drug.
The Shire-Boston Children's partnership is a true joint venture. It's managed by a joint steering committee with representation from both organizations, and is administered by the Technology and Innovation Development Office.
After the first review cycle in 2013, the joint steering committee selected two biologic R&D projects, from investigators Mark Puder, MD, PhD, of the Vascular Biology Program, and Mustafa Sahin, MD, PhD, of the Neurology Department, for funding and support.
In the news